Mismatch repair status and high expression of PD-L1 in nasopharyngeal carcinoma

References

• CallahanMKPostowMAWolchokJDTargeting T cell co-receptors for cancer therapyImmunity20164451069107827192570
   PubMed Web of Science ®Google Scholar
• TanSChenDLiuKCrystal clear: visualizing the intervention mechanism of the PD-1/PD-L1 interaction by two cancer therapeutic monoclonal antibodiesProtein Cell201671286687727815822
   PubMed Web of Science ®Google Scholar
• RibasAHamidODaudAAssociation of pembrolizumab with tumor response and survival among patients with advanced melanomaJAMA2016315151600160927092830
   PubMed Web of Science ®Google Scholar
• MedinaPJAdamsVRPD-1 pathway inhibitors: immuno-Oncology agents for restoring antitumor immune responsesPharmacotherapy201636331733426822752
   PubMed Web of Science ®Google Scholar
• BorghaeiHPaz-AresLHornLNivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancerN Engl J Med2015 Oct 22373171627163926412456
   PubMed Web of Science ®Google Scholar
• AnsellSMLesokhinAMBorrelloIPD-1 blockade with nivolumab in relapsed or refractory Hodgkin’s lymphomaN Engl J Med2015372431131925482239
   PubMed Web of Science ®Google Scholar
• AsciertoPABrugarolasJBuonaguroLPerspectives in immunotherapy: meeting report from the immunotherapy bridge (29–30 November, 2017, Naples, Italy)J Immunother Cancer2018616929996914
   PubMedGoogle Scholar
• GriggCRizviNAPD-L1 biomarker testing for non-small cell lung cancer: truth or fiction?J Immunother Cancer2016414827532023
   PubMed Web of Science ®Google Scholar
• GaronEBRizviNAHuiRPembrolizumab for the treatment of non-small-cell lung cancerN Engl J Med2015372212018202825891174
   PubMed Web of Science ®Google Scholar
• ReckMRodríguez-AbreuDRobinsonAGPembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancerN Engl J Med2016375191823183327718847
   PubMed Web of Science ®Google Scholar
• LeDTUramJNWangHPD-1 blockade in tumors with mismatch-repair deficiencyN Engl J Med2015372262509252026028255
   PubMed Web of Science ®Google Scholar
• LeDTDurhamJNSmithKNMismatch repair deficiency predicts response of solid tumors to PD-1 blockadeScience2017357634940941328596308
   PubMed Web of Science ®Google Scholar
• BruceJPYipKBratmanSVItoELiuFFNasopharyngeal cancer: molecular landscapeJCO2015332933463355
   PubMed Web of Science ®Google Scholar
• LeeAWMaBBNgWTChanATManagement of nasopharyngeal carcinoma: current practice and future perspectiveJ Clin Oncol201533293356336426351355
   PubMed Web of Science ®Google Scholar
• MaBBYLimWTGohBCAntitumor activity of nivolumab in recurrent and metastatic nasopharyngeal carcinoma: an international, multicenter study of the Mayo Clinic phase 2 Consortium (NCI-9742)J Clin Oncol201836141412141829584545
   PubMed Web of Science ®Google Scholar
• HsuCLeeSHEjadiSSafety and antitumor activity of pembrolizumab in patients with programmed Death-Ligand 1-positive nasopharyngeal carcinoma: results of the KEYNOTE-028 studyJ Clin Oncol201735364050405628837405
   PubMed Web of Science ®Google Scholar
• BacherJWFlanaganLASmalleyRLDevelopment of a fluorescent multiplex assay for detection of MSI-High tumorsDis Markers2004204–523725015528789
   PubMed Web of Science ®Google Scholar
• ChangAMVChioseaSIAltmanAPagdangananHAMaCProgrammed Death-Ligand 1 expression, microsatellite instability, Epstein-Barr virus, and human papillomavirus in nasopharyngeal carcinomas of patients from the PhilippinesHead Neck Pathol201711220321127807760
   PubMedGoogle Scholar
• HashmiAAAliRHussainZFMismatch repair deficiency screening in colorectal carcinoma by a four-antibody immunohistochemical panel in Pakistani population and its correlation with histopathological parametersWorld J Surg Oncol201715111628651545
   PubMedGoogle Scholar
• ChenWSwansonBJFrankelWLMolecular genetics of micro-satellite-unstable colorectal cancer for pathologistsDiagn Pathol20171212428259170
   PubMedGoogle Scholar
• SmyrkTCWatsonPKaulKLynchHTTumor-infiltrating lymphocytes are a marker for microsatellite instability in colorectal carcinomaCanc2001911224172422
   PubMed Web of Science ®Google Scholar
• AlexanderJWatanabeTWuTTRashidALiSHamiltonSRHistopathological identification of colon cancer with microsatellite instabilityAm J Pathol2001158252753511159189
   PubMed Web of Science ®Google Scholar
• YarchoanMHopkinsAJaffeeEMTumor mutational burden and response rate to PD-1 inhibitionN Engl J Med2017377252500250129262275
   PubMed Web of Science ®Google Scholar
• PeltomäkiPRole of DNA mismatch repair defects in the pathogenesis of human cancerJ Clin Oncol20032161174117912637487
   PubMed Web of Science ®Google Scholar
• ZysmanMSakaAMillarAKnightJChapmanWBapatBMethylation of adenomatous polyposis coli in endometrial cancer occurs more frequently in tumors with microsatellite instability phenotypeCanc Res2002621336633666
   PubMed Web of Science ®Google Scholar
• ChalmersZRConnellyCFFabrizioDAnalysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burdenGenome Med2017913428420421
   PubMed Web of Science ®Google Scholar
• AlexandrovLBJuYSHaaseKMutational signatures associated with tobacco smoking in human cancerScience2016354631261862227811275
   PubMed Web of Science ®Google Scholar
• AlexandrovLBNik-ZainalSWedgeDCSignatures of mutational processes in human cancerNature2013500746341542123945592
   PubMed Web of Science ®Google Scholar
• PursellZFIsozILundströmEBJohanssonEKunkelTAYeast DNA polymerase epsilon participates in leading-strand DNA replicationScience2007317583412713017615360
   PubMed Web of Science ®Google Scholar
• LiaoXZhaoLWuSMicrosatellite stability and mismatch repair proficiency in nasopharyngeal carcinoma may not predict programmed death-1 blockade resistanceOncotarget201786811328711329329348907
   PubMedGoogle Scholar
• ChanOSKowanetzMNgWTCharacterization of PD-L1 expression and immune cell infiltration in nasopharyngeal cancerOral Oncol201767526028351581
   PubMed Web of Science ®Google Scholar
• LeeVHLoAWLeungCYCorrelation of PD-L1 expression of tumor cells with survival outcomes after radical intensity-modulated radiation therapy for non-metastatic nasopharyngeal carcinomaPLoS One2016116e015796927341634
   PubMed Web of Science ®Google Scholar
• ZhangJFangWQinTCo-expression of PD-1 and PD-L1 predicts poor outcome in nasopharyngeal carcinomaMed Oncol20153238625702326
   PubMed Web of Science ®Google Scholar
• FangWZhangJHongSEBV-driven LMP1 and IFN-γ up-regulate PD-L1 in nasopharyngeal carcinoma: implications for oncotargeted therapyOncotarget2014523121891220225361008
   PubMed Web of Science ®Google Scholar
• QuYWangDYangLLiuHYCuiWCheYQExpression and clinical significance of programmed death ligand 1 in nasopharyngeal carcinomaMol Clin Oncol201891758129977542
   PubMed Web of Science ®Google Scholar
• ZhaoTLiCWuYLiBZhangBPrognostic value of PD-L1 expression in tumor infiltrating immune cells in cancers: a meta-analysisPLoS One2017124e017682228453554
   PubMed Web of Science ®Google Scholar
• KimHRHaSJHongMHPD-L1 expression on immune cells, but not on tumor cells, is a favorable prognostic factor for head and neck cancer patientsSci Rep2016613695627841362
   PubMedGoogle Scholar
• AtefiMAvramisELassenAEffects of MAPK and PI3K pathways on PD-L1 expression in melanomaClin Cancer Res201420133446345724812408
   PubMed Web of Science ®Google Scholar
• PardollDMThe blockade of immune checkpoints in cancer immunotherapyNat Rev Canc2012124252264
   PubMed Web of Science ®Google Scholar
• LeeVHKwongDLLeungTWThe addition of pretreatment plasma Epstein-Barr virus DNA into the eighth edition of nasopharyngeal cancer TNM stage classificationInt J Cancer144717131722
   PubMed Web of Science ®Google Scholar
• JiMFHuangQHYuXEvaluation of plasma Epstein-Barr virus DNA load to distinguish nasopharyngeal carcinoma patients from healthy high-risk populations in southern ChinaCancer201412091353136024477877
   PubMed Web of Science ®Google Scholar
• ChanKCZhangJChanATMolecular characterization of circulating EBV DNA in the plasma of nasopharyngeal carcinoma and lymphoma patientsCanc Res200363920282032
   PubMed Web of Science ®Google Scholar
• KimSTCristescuRBassAJComprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancerNat Med20182491449145830013197
   PubMed Web of Science ®Google Scholar
• LinHWeiSHurtEMHost expression of PD-L1 determines efficacy of PD-L1 pathway blockade-mediated tumor regressionJ Clin Invest2018128280581529337305
   PubMed Web of Science ®Google Scholar
• HirschFRMcelhinnyAStanforthDPD-L1 immunohistochemistry assays for lung cancer: results from phase 1 of the blueprint PD-L1 IHC assay comparison projectJ Thorac Oncol201712220822227913228
   PubMed Web of Science ®Google Scholar
• SmithJRobidaMDAcostaKQuantitative and qualitative characterization of two PD-L1 clones: SP263 and E1L3NDiagn Pathol20161114427189072
   PubMedGoogle Scholar
• XieRChungJYYlayaKFactors influencing the degradation of archival formalin-fixed paraffin-embedded tissue sectionsJ Histochem Cytochem201159435636521411807
   PubMed Web of Science ®Google Scholar
• WesterKWahlundESundströmCParaffin section storage and immunohistochemistry. Effects of time, temperature, fixation, and retrieval protocol with emphasis on p53 protein and MIB1 antigenAppl Immunohistochem Mol Morphol200081617010937051
   PubMedGoogle Scholar